Papulopustular Rosacea: Response to Treatment with Oral Azithromycin

Navarro, Marina; Guillén, Paloma Sánchez‐Pedreño; Martínez, Altea Esteve; Menchón, Teresa Martínez; Vélez, Raul Corbalán; Iniesta, J. Frías

doi:10.1016/j.adengl.2018.05.015

Cited by 5 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clarithromycin resulted in earlier and better outcomes than doxycycline (200 mg/day) in a comparative study 49 . Azithromycin is particularly useful in patients with tetracycline allergy or intolerance 51 …”

Section: Oral Therapymentioning

confidence: 99%

Rosacea management: A comprehensive review

Sharma¹,

Kroumpouzos

Kassir

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Rosacea is a chronic cutaneous disorder affecting primarily the face, characterized by erythema, transient or persistent, telangiectasia, and inflammatory lesions including papulo‐pustules and swelling. The essential component of the disease is the persistent erythema of facial skin. Episodes of flushing (acute‐subacute intermittent vasodilation) are common. Swelling and erythema of the nose along with dilatation of the pilosebaceous poral orifices, known as rhinophyma, can be noted in chronic cases. Rosacea affects up to 10% of the world population and is especially noted in fair‐skinned individuals aged 35–50. Women are affected more often than men. Several treatment modalities including topical medications, systemic drugs, lasers, and light‐based therapies have been used for the management of rosacea with variable results. Topical medications such as azelaic acid, metronidazole, and sulfacetamide/sulfur, oral antibiotics such as tetracyclines, and oral retinoids alone or, most commonly, in combination form the mainstay of treatment. Light therapies such as intense pulsed light and pulsed dye laser are best used for the erythemato‐telangiectatic type. Topical brimonidine, oxymetazoline, ivermectin, tacrolimus, pimecrolimus, low‐dose modified‐release tetracyclines and botulinum toxin are the new additions to the therapeutic armamentarium. This article provides a comprehensive review of the various therapies used for rosacea.

show abstract

Section: Oral Therapymentioning

confidence: 99%

Rosacea management: A comprehensive review

Sharma¹,

Kroumpouzos

Kassir

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…Although azithromycin is not approved for the treatment of rosacea, numerous studies have provided evidence for the clinical efficacy of the drug which is thought to be attributable primarily to its antiinflammatory properties [37]. Multiple therapeutic regimens for this indication have been reported in the literature.…”

Section: Azithromycinmentioning

confidence: 99%

“…Multiple therapeutic regimens for this indication have been reported in the literature. Most commonly, the drug is used at a dose of 500 mg 3 days a week (either on consecutive days or on Mondays, Wednesdays and Saturdays) for a period of 4-8 weeks [37,38]. If systemic treatment is necessary in pregnant women, azithromycin is the antibiotic of choice due to being categorised as pregnancy class B [39].…”

Section: Azithromycinmentioning

confidence: 99%

“…Wprawdzie azytromycyna nie jest zarejestrowana do leczenia trądziku różowatego, to jednak liczne badania wskazują na jej kliniczną skuteczność, głównie w wyniku od przeciwzapalnych właściwości leku [37]. W literaturze przedstawiono liczne schematy terapeutyczne stosowane w tym wskazaniu.…”

Section: Azytromycynaunclassified

“…W literaturze przedstawiono liczne schematy terapeutyczne stosowane w tym wskazaniu. Najczęściej podawana jest w dawce 500 mg przez 3 dni w tygodniu (kolejne lub w schemacie poniedziałek, środa, sobota) przez okres 4-8 tygodni [37,38]. W przypadku konieczności stosowania leczenia ogólnego u kobiet w ciąży jest antybiotykiem z wyboru, ponieważ zaliczana jest do kategorii B wg klasycznej kategoryzacji FDA [39].…”

Section: Azytromycynaunclassified

See 2 more Smart Citations

Rosacea – diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2. Treatment

Woźniacka¹,

Czuwara²,

Krasowska³

et al. 2022

View full text Add to dashboard Cite

Rosacea is a chronic inflammatory skin disease characterised by periods of remission and subsequent relapses typically provoked by environmental factors. Eruptions located on the face are easily visible and may be difficult to conceal, which leads to a decrease in patients' self-esteem, quality of life, and general well-being. Since the aetiology of rosacea is multifactorial and not entirely understood, and the clinical characteristics and course of the disease are heterogeneous, therapy may be challenging. While a complete cure is not possible, in the majority of cases clinical improvement and long-term remission are satisfying both to the patient and physician. In recent years, the therapeutic approach has been significantly modified. Currently, the focus is placed on the need to personalise the treatment process and adapt it to the patients' phenotypic characteristics. Combination therapies and new variants of existing topical and systemic drugs are increasingly being recommended. The mainstays of therapy are antiinflammatory agents. Proper skin care -along with the identification and avoidance of factors known to trigger consecutive episodes of rosacea -are also essential.

show abstract